News

(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) Monday said its Phase 3 HELIOS-B study evaluating vutrisiran in Transthyretin amyloid cardiomyopathy (ATTR-CM) met primary goal.

In the study, patients with ATTR-CM were randomized to receive either vutrisiran or placebo for a period of up to 36 months. Results from the study showed statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular (CV) events in both the overall population and in the monotherapy population. Additionally, treatment with vutrisiran reduced all-cause mortality in the overall population and in the monotherapy population up to month 42.

Alnylam plans to file global regulatory submissions starting later this year including a supplmental New Drug Application to the FDA seeking priority review.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.